Micron Technology, Inc. 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended June 4, 2009. Micron Technology, Inc. is a global manufacturer of semiconductor devices, primarily DRAM and NAND Flash memory (Memory segment) and CMOS image sensors (Imaging segment). The company operates in a severe industry downturn characterized by significant oversupply and declining average selling prices (ASPs), exacerbated by global economic conditions.
Key Financial Metrics
| Metric | Q3 2009 | Q3 2008 | 9 Months 2009 | 9 Months 2008 |
|---|---|---|---|---|
| Net Sales | $1,106 million | $1,498 million | $3,501 million | $4,392 million |
| Gross Margin | $107 million (10%) | $48 million (3%) | ($609 million) (-17%) | $10 million (0%) |
| Operating Loss | ($246 million) | ($225 million) | ($1,626 million) | ($1,257 million) |
| Net Loss | ($290 million) | ($236 million) | ($1,747 million) | ($1,275 million) |
| Loss Per Share (Diluted) | ($0.36) | ($0.30) | ($2.22) | ($1.65) |
| Cash and Equivalents | $1,306 million | $1,243 million (Aug 2008) | N/A | |
| Total Debt | $3,124 million | $2,726 million (Aug 2008) | N/A | |
| Operating Cash Flow (9mo) | N/A | $849 million | $775 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 26% year-over-year (Q3 2009 vs. Q3 2008) due to a 53% decline in DRAM ASPs and a 58% decline in NAND Flash ASPs, partially offset by increased unit volumes.
- Margin Improvement: Gross margin improved to 10% in Q3 2009 from 3% in Q3 2008, driven by cost reductions and the sale of inventory previously written down in prior quarters. However, the nine-month gross margin remained negative at -17%.
- Restructuring: The company initiated restructure plans in 2009, including the phase-out of 200mm wafer manufacturing at its Boise facility by year-end. Restructure charges were $19 million for Q3 2009 and $58 million for the nine months ended June 4, 2009.
- Goodwill Impairment: In Q2 2009, the company wrote off $58 million of goodwill associated with the Imaging segment due to severe declines in sales and profitability.
- Equity Method Losses: The company recorded a $45 million loss in Q3 2009 from its equity method investments (Inotera and MeiYa), reflecting the partners' losses.
Guidance, Outlook, and Risks
- Capital Expenditures: The company significantly reduced planned capital expenditures for 2009. It expects capital spending of approximately $100 million for Q4 2009 and $700 million for 2010.
- Liquidity: Liquidity is highly dependent on product ASPs and capital expenditure timing. The company has $1.3 billion in cash and equivalents but notes that access to external financing may be difficult due to credit market conditions.
- Legal Proceedings: Significant risks include ongoing patent litigation with Rambus (appeal pending on spoliation decision), antitrust class actions regarding DRAM and SRAM price-fixing, and securities class actions. The company settled SRAM litigation in March 2009, pending court approval.
- Aptina Sale: On July 10, 2009 (subsequent to the period end), the company sold a 65% interest in its Imaging subsidiary, Aptina, retaining a 35% stake. This transaction is expected to reduce Imaging R&D costs but may result in lower gross margins on wafer supply agreements.
- Accounting Changes: The company is evaluating the impact of new accounting standards (SFAS 167, APB 14-1, SFAS 141(R), SFAS 160) to be adopted in 2010 and 2011, which could affect debt accounting and consolidation of variable interest entities.
Investor Verification Checklist
- Inventory Valuation: Verify the adequacy of inventory reserves given the volatile ASPs; the company recorded $603 million in inventory write-downs for the first nine months of 2009.
- Debt Covenants: Confirm compliance with debt covenants, particularly for the TECH joint venture, which has liquidity and leverage ratios that could trigger default if not met.
- Joint Venture Exposure: Assess the financial health and future capital requirements of joint ventures (IM Flash, TECH, Inotera, MeiYa), as the company is obligated to purchase capacity and share losses.
- Legal Reserves: Review the status of the Rambus appeal and the potential financial impact of the pending antitrust and securities litigation settlements.
- Aptina Transition: Monitor the operational impact of the Aptina sale and the terms of the new wafer supply agreement on future Imaging segment margins.